Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
24AUG

J&J backs Trimtech seed to GBP35.6m

2 min read
16:40UTC

Trimtech Therapeutics extended its seed round to GBP35.6m after Johnson & Johnson Innovation and BGF added $14m and took board seats.

← Back to UKRI's sponsor department no longer existsJump to analysis ↓
TechnologyDeveloping
Key takeaway

J&J and BGF bought board seats at Trimtech, backing UK biotech that domestic venture is not funding.

Trimtech Therapeutics, a Cambridge biotech, extended its seed round to GBP35.6m after Johnson & Johnson Innovation (JJDC), the US pharmaceutical group's venture Arm, and BGF, a UK growth-capital investor, added $14m and both took board seats 1. The company designs targeted protein degraders, molecules that tag a disease-causing protein for the cell's own disposal system rather than merely blocking it, aimed at neurodegenerative and inflammatory disease.

The extension builds on a GBP25m seed led by Cambridge Innovation Capital in 2025. Strategic pharmaceutical capital, not UK venture, is funding the deep end here.

It is the same pattern as SAP taking a stake in Conduct to hedge its own migration deadline : a corporate investor buys a board seat to watch a technology it may later need, cheaper than building or acquiring it outright. For an early biotech, that visibility cuts both ways, bringing a route to market alongside an incumbent already inside the boardroom.

Deep Analysis

In plain English

Trimtech Therapeutics is a Cambridge company developing medicines that use 'targeted protein degraders', molecules that tag disease-causing proteins so the body's own cells break them down naturally, rather than simply blocking them the way most drugs do. The company has just topped up its earliest funding round to £35.6m after Johnson & Johnson's venture arm and BGF, a UK growth-capital investor, each put in money and took a seat on its board. A board seat gives an investor a formal say in how the company is run, which for a large drugmaker like Johnson & Johnson often signals interest in eventually licensing or buying the technology.

Sources:UKTN
Mentions:Laverock Therapeutics →Johnson & Johnson Innovation (JJDC) →BGF →Cambridge Innovation Capital →Cambridge →Conduct →SAP →Trimtech Therapeutics →
First Reported In

Update #10 · AI takes record 44% as UK equity shrinks

UKTN· 4 Jul 2026
Read original →
Causes and effects
Caused by
Conduct takes $60m as SAP buys in
SAP's strategic stake in Conduct set the template of a corporate investor buying board-seat visibility, now repeated with J&J Innovation and BGF in Trimtech.
Occurred 17 Jun 2026
Read story →
This Event
J&J backs Trimtech seed to GBP35.6m
Corporate pharmaceutical capital, not UK venture, is funding the deep end of British biotech and buying boardroom visibility with it.
Different Perspectives
Highland Europe
Highland Europe
Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.
Integrity Growth Partners
Integrity Growth Partners
The Los Angeles firm put £16.1m into Prevalent AI on 24 August, the London GCHQ-alumni company's first outside capital, specifically to fund its US expansion. Its stake is a single commercial bet on one UK deep-tech founder's American growth, not a comment on which department UKRI answers to this month.
Temasek
Temasek
Temasek led PhysicsX's Series C on 30 July, into which the British Business Bank put $25m through British Growth Partnership Fund I. State-backed pension capital rides behind a foreign-led growth round while UK weekly tech funding fell 72% to £102.95m across nine rounds three weeks later.
Innovate UK's Women in Innovation cohort
Innovate UK's Women in Innovation cohort
Sixty-one founders won £75,000 grants from Innovate UK on 5 August, the programme's largest-ever cohort, with a further 39 highly commended founders taking support without cash. For these founders the sponsorship dispute over UKRI's parent department is academic: the money and mentoring arrived exactly as scheduled.
Financial Conduct Authority
Financial Conduct Authority
The FCA added five fintechs, ClearScore, Modulr, Teya, Urban Jungle and Zilch, to its Scale-up Unit on 7 August, the first cohort it regulates solely rather than jointly with the Prudential Regulation Authority. The unit's expansion is a routine regulatory build-out running on its own timetable, unconnected to the sponsorship dispute over its sister department UKRI.
Cabinet Office
Cabinet Office
The Cabinet Office ran the DSIT-to-BIST transfer as a standard cross-government machinery change, the kind gov.uk pages and framework documents routinely take months to catch up with after any department is abolished or renamed. Officials treat the paperwork lag as administrative sequencing, not dysfunction: funding and grant-approval layers moved first because they had to keep working.